Jagsonpal Completes Group Pharma Wellness Portfolio Acquisition
Jagsonpal Pharmaceuticals Ltd · Others (Uncategorized) · 01 Oct 2026, 10:27 pm
Jagsonpal Completes Group Pharma Wellness Portfolio Acquisition Jagsonpal Pharmaceuticals consummated the acquisition of Group Pharmaceuticals' Wellness Portfolio on 1st Oct'26. The deal comprises an upfront consideration of ~₹23.7 Cr and maximum performance-linked deferred consideration of ~₹23.0 Cr tied to FY28 sales. The acquired business generated ~₹24.6 Cr revenue in FY26 with a ~78.0% gross margin across 6 states, led by brands Hemozink and Sudin. Supported by a ~₹170 Cr cash balance as of Q1FY27, this margin-accretive transaction advances Jagsonpal's inorganic strategy toward its ₹500 Cr revenue target by FY28.
Original exchange filing (PDF)
More announcements from Jagsonpal Pharmaceuticals Ltd
- Earning call transcript for Jagsonpal Pharmaceuticals Limited Q2 FY 27 Earning Conference Call on October 29, 2026 at 2:00 P.M · 03 Nov 2026
- Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY27 Earnings Conference call on October 29, 2026 at 02:00 P.M. · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter September 30, 2026 · 29 Oct 2026
- Press Release for Unaudited Financial Results for the quarter ended September 30, 2026. · 29 Oct 2026
- Unaudited Financial Results (Standalone & Consolidated for the quarter and half year ended September 30, 2026. · 28 Oct 2026
- Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- Outcome of Board Meeting held on October 28, 2026 along with Unaudited Financial Results(Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 28 Oct 2026
- JAGSONPAL PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 28 Oct 2026
